NCT01069575 2019-03-19
Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer
Shiga University
Phase 1 Completed
Clinical Trials
12 trialsNCT01069640 2019-03-19
Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer
Shiga University
Phase 1 Completed
NCT00624182 2015-06-23
Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer
Akita University Hospital
Phase 1 Suspended
NCT00753844 2012-04-06
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer
Kinki University
Phase 1 Completed
NCT00632333 2011-07-21
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer
Teikyo University
Phase 1 Unknown
NCT00676949 2011-06-23
peptidevac
Kyushu University
Phase 1 Completed
NCT00681252 2009-11-19
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer
Tokyo University
Phase 1/2 Completed
NCT00681421 2009-11-19
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer
Tokyo University
Phase 1/2 Completed
NCT00681577 2009-11-19
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer
Tokyo University
Phase 1/2 Completed
NCT00561275 2008-07-15
Safety Study of Multiple Peptide Vaccine to Esophageal Cancer
Japanese Foundation for Cancer Research
Phase 1 Completed
NCT00682227 2008-05-29
Peptide Vaccination in Treating Patients With Esophageal Cancer
University of Yamanashi
Phase 1 Unknown
NCT00674258 2008-05-14
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer
Tokyo University
Phase 1/2 Unknown